Inventiva SA
IVA3.350USD
+0.130+4.04%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
0.00Marktkapitalisierung
--KGV TTM
mehr Informationen über Inventiva SA Unternehmen
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Unternehmensinformationen
BörsenkürzelIVA
Name des UnternehmensInventiva SA
IPO-datumFeb 15, 2017
CEOMr. Frederic Cren
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
Geschäftsjahresende- -
Addresse50 rue de Dijon
StadtDAIX
BörseEuronext Paris
LandFrance
Postleitzahl21121
Telefon33380447500
Websitehttps://inventivapharma.com/
BörsenkürzelIVA
IPO-datumFeb 15, 2017
CEOMr. Frederic Cren
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Head of Human Resources
Head of Human Resources
--
--
Mr. Frederic Cren
Mr. Frederic Cren
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer, Deputy General Manager
Chief Financial Officer, Deputy General Manager
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Executive Vice President - Regulatory Affairs and Quality Assurance
Executive Vice President - Regulatory Affairs and Quality Assurance
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Dr. Jason Campagna, M.D., Ph.D.
Dr. Jason Campagna, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lucy Lu, M.D.
Dr. Lucy Lu, M.D.
Independent Director
Independent Director
--
--
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Head of Human Resources
Head of Human Resources
--
--
Mr. Frederic Cren
Mr. Frederic Cren
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer, Deputy General Manager
Chief Financial Officer, Deputy General Manager
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Thu, Apr 17
Aktualisiert: Thu, Apr 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Yiheng Capital Management, L.P.
2.76%
New Enterprise Associates (NEA)
1.53%
BVF Partners L.P.
0.72%
Commonwealth Financial Network
0.06%
Wealth Enhancement Advisory Services, LLC
0.02%
Other
94.91%
Aktionäre
Aktionäre
Anteil
Yiheng Capital Management, L.P.
2.76%
New Enterprise Associates (NEA)
1.53%
BVF Partners L.P.
0.72%
Commonwealth Financial Network
0.06%
Wealth Enhancement Advisory Services, LLC
0.02%
Other
94.91%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
2.84%
Venture Capital
1.53%
Hedge Fund
0.72%
Other
94.91%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
19
4.87M
5.09%
-648.41K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
2023Q3
22
4.86M
11.53%
-1.45M
2023Q2
24
4.83M
11.47%
-1.47M
2023Q1
26
5.13M
12.18%
-904.48K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Yiheng Capital Management, L.P.
2.64M
2.76%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.46M
1.53%
--
--
Mar 31, 2025
BVF Partners L.P.
686.04K
0.72%
--
--
May 07, 2025
Commonwealth Financial Network
54.49K
0.06%
+12.49K
+29.73%
Mar 31, 2025
Wealth Enhancement Advisory Services, LLC
10.71K
0.01%
+10.71K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
4.70K
0%
--
--
May 31, 2025
UBS Financial Services, Inc.
708.00
0%
-608.54K
-99.88%
Mar 31, 2025
BNP Paribas Securities Corp. North America
500.00
0%
-1.40K
-73.68%
Mar 31, 2025
Covestor, Ltd.
402.00
0%
--
--
Mar 31, 2025
Carson Wealth Management Group
--
0%
-100.00
-100.00%
Mar 31, 2024
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
